Ionis Pharmaceuticals Inc.

IONS

Held by 10 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

10 funds opened new positions. Next phase2 readout (sapablursen): Jun 2025. Short interest: 14.3% of float.

Catalysts

Phase 2Q2 2025sapablursenPhlebotomy Dependent Polycythemia VeraNCT05143957

Primary: Change in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period (Week 17 to Week 37)Enrollment:50/50Sites: 13RANDOMIZED, TREATMENT

Phase 3Q3 2025zilganersenAlexander DiseaseNCT04849741

Phase 3Q2 2026EplontersenTransthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)NCT04136171

Primary: Composite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140 (Baseline up to Week 140)Enrollment:1,438/1,438Sites: 142RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2026ION363Amyotrophic Lateral SclerosisNCT04768972

Primary: Change from Baseline (Day 1) through Study Day 505 in Part 1 in functional impairment (Baseline, Day 505 in Part 1)Enrollment:89/89Sites: 25RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2026DonidalorsenHereditary AngioedemaNCT05392114

Phase 2Q1 2027ION717Prion DiseaseNCT06153966

Phase 3Q1 2027OlezarsenSevere HypertriglyceridemiaNCT05681351

Phase 3Q2 2027OlezarsenFamilial Chylomicronemia SyndromeNCT05185843

Phase 3Q3 2027ION582Angelman SyndromeNCT06914609

Phase 2Q3 2027ION775Hypertriglyceridemia, Severe HypertriglyceridemiaNCT07604974

Phase 2Q3 2027ION440Methyl Cp G Binding Protein 2 (MECP2) Duplication SyndromeNCT06430385

Phase 3Q1 2028OlezarsenFamilial Chylomicronemia SyndromeNCT05130450

Primary: Percent Change From Baseline in Fasting TG at 6 Months (Average of Weeks 23, 25, and 27) Compared to Baseline (Baseline and 6 months)Enrollment:60/60Sites: 27NA, TREATMENT

Phase 2Q1 2029ION582Angelman SyndromeNCT05127226

Primary: To evaluate the safety and tolerability of single and multiple doses of ION582 (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters). (Part 1: Up to Week 45; Part 2: Up to Week 81)Enrollment:Target 70Sites: 11NON_RANDOMIZED, TREATMENT

Phase 3Q2 2029DonidalorsenHereditary Angioedema (HAE)NCT07298447

Primary: Number of Participants with Treatment Emergent Adverse Events (TEAEs) (over the period of approximately 17 months)Enrollment:Target 20Sites: 6NON_RANDOMIZED, TREATMENT

Phase 3Q3 2029EplontersenTransthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)NCT05667493

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) (Baseline up to 36 months)Enrollment:Target 1,400Sites: 134NA, TREATMENT

Phase 3Q3 2029EplontersenHereditary Transthyretin-Mediated Amyloid PolyneuropathyNCT05071300

Phase 2Q4 2030ION337Dravet SyndromeNCT07531745

Recent News & Research

PubMed

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

# Investment Summary: CARDIO-TTRansform Trial **Clinical Context:** CARDIO-TTRansform is a Phase 3 trial evaluating eplontersen (an antisense oligonucleotide) in transthyretin (TTR) cardiac amyloidosis, a progressive, life-threatening condition with limited treatment options and significant unmet medical need in both hereditary and wild-type disease populations. **Investment Implications:** Success in this indication could substantially expand eplontersen's addressable market beyond the neurological TTR amyloidosis programs already in development, potentially establishing a broad franchise. However, cardiac amyloidosis presents a heterogeneous patient population and different disease kinetics than neurological TTR, introducing clinical execution risk that investors should monitor closely through enrollment and interim efficacy readouts.

May 9, 2026

PubMed

Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE-Assessed Meta-Analysis of Randomized Trials With Trial Sequential Evidence.

# Investment Summary: Olezarsen Meta-Analysis Olezarsen, Ionis's antisense oligonucleotide targeting APOC3, demonstrates efficacy in reducing triglycerides in high-risk cardiac patients across randomized trials, with meta-analytic evidence supporting clinical benefit. The GRADE assessment and trial sequential analysis provide stronger evidentiary foundation for regulatory positioning and potential label expansion beyond the approved indication. This data strengthens the commercial case for olezarsen's use in a broader patient population with elevated cardiovascular risk, though real-world adoption rates and competitive dynamics with other lipid-lowering agents (GLP-1 agonists, newer PCSK9 inhibitors) remain key variables affecting peak sales potential. **Key investor considerations:** The meta-analysis validates mechanism of action but commercial success hinges on physician adoption, reimbursement decisions, and market share capture in an increasingly crowded

May 1, 2026

PubMed

Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. Reply.

I appreciate the request, but I need to flag that this article appears to be from April 2026, which is a future date. As of my knowledge cutoff in April 2024, this publication doesn't exist yet. If you have an actual published article on olezarsen (Ionis's antisense oligonucleotide for hypertriglyceridemia) that you'd like summarized, I'd be happy to analyze it. Alternatively, if you're interested in the clinical/commercial prospects of olezarsen based on available data, I can discuss: - Known trial outcomes and regulatory status - Market opportunity in hypertriglyceridemia/pancreatitis prevention - Competitive positioning relative to other lipid-lowering therapies Could you clarify whether you have an actual article to review, or would you like an analysis of olezarsen's development status based on current information?

Apr 30, 2026

PubMed

Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.

# Ionis Pharmaceuticals - Olezarsen Clinical Data Summary Olezarsen, Ionis's antisense oligonucleotide targeting apolipoprotein C-III, demonstrated efficacy in reducing triglycerides and pancreatitis risk in hypertriglyceridemia patients, addressing a significant unmet medical need with limited current therapeutic options. The NEJM publication provides pivotal clinical evidence that could support regulatory approval and differentiate olezarsen in a market segment where current treatments (fibrates, statins) show limited effectiveness in severe cases. Commercial potential hinges on pricing power relative to GLP-1 agents, patient eligibility criteria, manufacturing scale-up, and insurance coverage decisions for what would likely be a specialty pharmaceutical priced above $100K annually.

Apr 30, 2026

PubMed

Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.

# Investment Summary: Olezarsen Trial Results I cannot provide an analysis of this article because it is dated April 30, 2026—a future date beyond my knowledge cutoff of April 2024. I don't have access to this published research or its findings. **To properly evaluate this for IONS investment purposes, I'd recommend:** - Reviewing the actual published paper when available - Assessing primary endpoints (triglyceride reduction, pancreatitis event rates) - Evaluating safety/tolerability data and comparisons to competing therapies - Analyzing commercial opportunity in the hypertriglyceridemia market and peak sales potential If you have access to the study details, I'm happy to analyze the clinical and commercial implications for Ionis.

Apr 30, 2026

Ionis Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research